Global Immunotherapy Drugs 2016-2020

PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
• Assumptions
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Overview: Immunotherapy
• Types of immunotherapy
• Key events
• Reimbursement policies
• Orphan drug designation and regulatory approvals
PART 06: Pipeline portfolio
• Anticipated number of immuno-oncology pipeline assets with single and multiple indications by 2020
PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 08: Market segmentation by type of immunotherapy
• mAbs
• Immune checkpoint inhibitors
• Vaccines
• Non-specific immunotherapies
PART 09: Market segmentation by therapy area
PART 10: Geographical segmentation
• Global immunotherapy drugs market by geographical segmentation 2015-2020
• Immunotherapy drugs market in Americas
• Immunotherapy drugs market in EMEA
• Immunotherapy drugs market in APAC
PART 11: Market drivers
• Growing prevalence of cancer and autoimmune diseases
• Rise in older population
• Increase in demand for mAbs
• Patient assistance programs
• Promising pipeline
PART 12: Impact of drivers
PART 13: Market challenges
• Patent expiries of top-selling drugs
• High costs of biologicals
• Poor diagnosis and screening
• Adverse effects
• Stringent regulations
PART 14: Impact of drivers and challenges
PART 15: Market trends
• Increase in awareness programs
• Emergence of targeted and combination therapies
• Emergence of biosimilars
• Strategic alliances
• Expected entry of novel vaccines
PART 16: Vendor landscape
• Competitive scenario
• Market share analysis 2015
• F. Hoffmann-La Roche
• AbbVie
• Johnson & Johnson
• Merck
• Amgen
• BMS
• Other prominent vendors
PART 17: Appendix
• List of abbreviations
PART 18: Explore Technavio
?



List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Types of immunotherapy
Exhibit 03: Key events in discovery and approvals of immunotherapy drugs
Exhibit 04: Immunotherapy drugs approved by US FDA in 2015
Exhibit 05: US FDA orphan drug designations and approvals list for immunotherapy drugs
Exhibit 06: EU orphan drug designations and approvals list for immunotherapy drugs
Exhibit 07: Phase III pipeline molecules for mAbs
Exhibit 08: Phase II pipeline molecules for mAbs
Exhibit 09: Phase I pipeline molecules for mAbs
Exhibit 10: Pipeline molecules for immune checkpoint inhibitors
Exhibit 11: Phase III pipeline molecules for vaccines
Exhibit 12: Phase II pipeline molecules for vaccines
Exhibit 13: Phase I pipeline molecules for vaccines
Exhibit 14: Near-launch immuno-oncology pipeline assets
Exhibit 15: Global immunotherapy drugs market 2015-2020 ($ billions)
Exhibit 16: Factors influencing global immunotherapy drugs market
Exhibit 17: Challenges faced by US immunologists while prescribing immunotherapy drugs 2015
Exhibit 18: SWOT analysis of global immunotherapy drugs market
Exhibit 19: Five forces analysis
Exhibit 20: Market segmentation by type of immunotherapy drug
Exhibit 21: Timeline of mAbs approval for cancer by US FDA
Exhibit 22: Timeline of mAbs approval for autoimmune, respiratory, and ophthalmic diseases by US FDA
Exhibit 23: Global mAbs market 2015-2020 ($ billions)
Exhibit 24: Key drivers and challenges of global monoclonal antibodies drugs market
Exhibit 25: Top vendor offerings in global mAbs market
Exhibit 26: Global immune checkpoint inhibitors market 2015-2020 ($ billions)
Exhibit 27: Key driver and challenge for global immune checkpoint inhibitors market
Exhibit 28: Top vendor offerings in global immune checkpoint inhibitors market
Exhibit 29: Global vaccines market 2015-2020 ($ billions)
Exhibit 30: Segmentation of global vaccines market by application 2015
Exhibit 31: Key drivers and challenges of global vaccines market
Exhibit 32: Top vendor offerings in global vaccines market
Exhibit 33: Global non-specific immunotherapies market 2015-2020 ($ billions)
Exhibit 34: Key drivers and challenges of global non-specific immunotherapies market
Exhibit 35: Top vendor offerings in global non-specific immunotherapies market
Exhibit 36: Segmentation of global immunotherapy drugs market by type of immunotherapy 2015
Exhibit 37: Global immunotherapy drugs market; YoY revenue and growth rate based on type of immunotherapy 2015-2020 ($ billions)
Exhibit 38: Global immunotherapy drugs market segmentation by therapy area
Exhibit 39: Segmentation of global immunotherapy drugs market by therapy area 2015
Exhibit 40: Segmentation of global immunotherapy drugs market by geography 2015
Exhibit 41: Global immunotherapy drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 42: Immunotherapy drugs market in Americas 2015-2020 ($ billions)
Exhibit 43: Market share in the Americas by type of immunotherapy 2015
Exhibit 44: Immunotherapy drugs market in EMEA 2015-2020 ($ billions)
Exhibit 45: Market share in Europe by type of immunotherapy 2015
Exhibit 46: Immunotherapy drugs market in APAC 2015-2020 ($ billions)
Exhibit 47: Market share in APAC by type of immunotherapy 2015
Exhibit 48: Global immunotherapy drugs market: YoY revenue and growth based on geography 2015-2020 ($ billions)
Exhibit 49: Global incidence of cancers 2015 and 2020
Exhibit 50: Population aged 60 years and over: World, developed, and developing regions (millions)
Exhibit 51: Patient assistance programs for immunotherapy drugs
Exhibit 52: Some pipeline molecules for immunotherapy drugs
Exhibit 53: Impact of drivers
Exhibit 54: Approvals and patent expiries of top-selling immunotherapy drugs
Exhibit 55: Average annual treatment cost per patient for some immunotherapy drugs 2014 ($ millions)
Exhibit 56: Impact of drivers and challenges
Exhibit 57: Expected combination regimen launches in immune-oncology 2015-2020
Exhibit 58: Market share analysis of top vendors0
Exhibit 59: Competitive assessment of top 10 immunotherapy drugs 2015 ($ billions)1
Exhibit 60: YoY sales comparison of top five immunotherapy drugs 2013-2015 ($ billions)1
Exhibit 61: F. Hoffmann-La Roche: Immunotherapy drugs segmentation by revenue 20152
Exhibit 62: F. Hoffmann-La Roche: Top-selling immunotherapy drugs 20152
Exhibit 63: F. Hoffmann-La Roche: YoY revenue and growth rate of MabThera/Rituxan (oncology and immunology indications) 2013-2015 ($ billions)
Exhibit 64: F. Hoffmann-La Roche: YoY revenue and growth rate of MabThera/Rituxan (immunology indications only) 2013-2015 ($ billions)4
Exhibit 65: F. Hoffmann-La Roche: YoY revenue and growth rate of Actemra/RoActemra 2013-2015 ($ billions)5
Exhibit 66: F. Hoffmann-La Roche: Actemra/RoActemra geographic segmentation by revenue 20155
Exhibit 67: F. Hoffmann-La Roche: MabThera/Rituxan geographic segmentation by revenue 20156
Exhibit 68: F. Hoffmann-La Roche: YoY revenue and growth rate of Avastin 2012-2015 ($ billions)7
Exhibit 69: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin 2012-2015 ($ billions)8
Exhibit 70: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin in US 2013-2015 ($ billions)8
Exhibit 71: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin in EU 2013-2015 ($ billions)8
Exhibit 72: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin in Japan 2013-2015 ($ millions)9
Exhibit 73: F. Hoffmann-La Roche: YoY revenue and growth rate of Perjeta 2012-2015 ($ billions)0
Exhibit 74: F. Hoffmann-La Roche: YOY revenue and growth rate of Kadcyla 2013-2015 ($ billions)1
Exhibit 75: F. Hoffmann-La Roche: Key takeaways3
Exhibit 76: AbbVie: Immunotherapy drugs segmentation by revenue 20154
Exhibit 77: AbbVie: YoY revenue and growth rate of HUMIRA 2013-2015 ($ billions)5
Exhibit 78: AbbVie: YoY revenue and growth rate of HUMIRA in US 2013-2015 ($ billions)5
Exhibit 79: AbbVie: YoY revenue and growth rate of HUMIRA in ROW 2013-2015 ($ billions)5
Exhibit 80: AbbVie: Sales of HUMIRA in major markets 20156
Exhibit 81: AbbVie: Key takeaways7
Exhibit 82: Johnson & Johnson: Key immunotherapy drugs segmentation by revenue 20158
Exhibit 83: Johnson & Johnson: Top-selling immunotherapy drugs 20158
Exhibit 84: Johnson & Johnson: YoY revenue and growth rate of Remicade 2012-2015 ($ billions)9
Exhibit 85: Johnson & Johnson: YoY revenue and growth rate of Stelara 2012-2015 ($ billions)0
Exhibit 86: Johnson & Johnson: YoY revenue and growth rate of Stelara in US 2012-2015 ($ billions)0
Exhibit 87: Johnson & Johnson: YoY revenue and growth rate of Stelara in ROW 2012-2015 ($ millions)0
Exhibit 88: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 2012-2015 ($ billions)1
Exhibit 89: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria in the US 2012-2015 ($ billions)1
Exhibit 90: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria in ROW 2012-2015 ($ billions)2
Exhibit 91: Johnson & Johnson: Key takeaways3
Exhibit 92: Merck: Business segmentation by revenue 20154
Exhibit 93: Merck: Immunotherapy drugs segmentation by revenue 20155
Exhibit 94: Merck: Top-selling immunotherapy drugs 20156
Exhibit 95: Merck: YoY revenue and growth rate of Gardasil/Gardasil9 2012-2015 ($ billions)7
Exhibit 96: Merck: YoY revenue and growth rate of ProQuad/M-M-R II/Varivax 2012-2015 ($ billions)8
Exhibit 97: Merck: YoY revenue and growth rate of Zostavax 2012-2015 ($ millions)8
Exhibit 98: Merck: YoY revenue and growth rate of Pneumovax 23 2012-2015 ($ millions)9
Exhibit 99: Merck: YoY revenue and growth rate of RotaTeq 2012-2015 ($ millions)9
Exhibit 100: Merck: Key takeaways2
Exhibit 101: Amgen: Top-selling immunotherapy drugs 20153
Exhibit 102: Amgen: YoY revenue and growth rate of Enbrel in US and Canada 2012-2015 ($ billions)4
Exhibit 103: Amgen: YoY revenue and growth rate of Enbrel in US 2012-2015 ($ billions)4
Exhibit 104: Amgen: YoY revenue and growth rate of Enbrel in Canada 2012-2015 ($ millions)4
Exhibit 105: Amgen: YoY revenue and growth rate generated from net product sales of Xgeva 2012-2015 ($ billions)5
Exhibit 106: Amgen: YoY revenue and growth rate generated from net product sales of Prolia 2012-2015 ($ billions)5
Exhibit 107: Amgen: YoY revenue and growth rate of Vectibix in US 2012-2015 ($ millions)6
Exhibit 108: Amgen: YoY revenue and growth rate of Vectibix in ROW 2012-2015 ($ millions)6
Exhibit 109: Amgen: Key takeaways9
Exhibit 110: BMS: Business segmentation by revenue 20150
Exhibit 111: BMS: Immunotherapy drugs segmentation by revenue 20150
Exhibit 112: BMS: Top-selling immunotherapy drugs 20151
Exhibit 113: BMS: YoY revenue and growth rate of Orencia 2012-2015 ($ billions)2
Exhibit 114: BMS: YoY revenue and growth rate generated from net product sales of Yervoy 2012-2015 ($ billions)2
Exhibit 115: BMS: YoY revenue and growth rate of Erbitux in US, Canada, and Japan 2012-2015 ($ millions)3
Exhibit 116: BMS: Key takeaways

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.

Menu 3

Eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.